enVVeno Medical
NVNO
22 hedge funds and large institutions have $10.4M invested in enVVeno Medical in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
76% more capital invested
Capital invested by funds: $5.9M → $10.4M (+$4.51M)
0% more ownership
Funds ownership: 0.58% → 0.58% (+0%)
4% less funds holding
Funds holding: 23 → 22 (-1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$188K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$84.6K |
| 3 |
FA
Fermata Advisors
Sonoma,
California
|
+$56.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$45.9K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$30.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$139K |
| 2 |
Squarepoint
New York
|
-$40.9K |
| 3 |
Renaissance Technologies
New York
|
-$36K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$15.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Renaissance Technologies
New York
| – | -$36K | -336 | Closed |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$334 | -2 | -67% |
|
NVNO Hedge Fund Activity: Q3 2023 in Review
22 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q3 2023, worth a combined $10.4M — up 76% from $5.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NVNO and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was UBS O'Connor, adding an estimated $188K. The largest seller was Citadel Advisors, exiting entirely with an estimated $139K sold.
- 22 institutional investors held enVVeno Medical (NVNO) as of Q3 2023, down from 23 in Q2 2023.
- Funds reported $10.4M of enVVeno Medical stock for Q3 2023, up 76% quarter-over-quarter.
- 3 funds opened new enVVeno Medical positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest enVVeno Medical buyer in Q3 2023 was UBS O'Connor, an estimated $188K added.
- The largest enVVeno Medical seller in Q3 2023 was Citadel Advisors, an estimated $139K sold.
Based on aggregated 13F filings for Q3 2023.